We are live on ! Find out more
TGI

TRV GP II Portfolio holdings

AUM $1.34M
1-Year Est. Return 67.55%
This Fund
S&P 500
This Quarter Est. Return
-30.86%
1 Year Est. Return
-67.55%
3 Year Est. Return
-20.84%
5 Year Est. Return
-49.87%
10 Year Est. Return
–
AUM
$33.9M
AUM Growth
-$124M
Cap. Flow
-$105M
Cap. Flow %
-308.95%
Top 10 Hldgs %
100%
Holding
3
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$87.6M
2
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$17.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JNCE
1
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$30.2M 89.29%
4,447,829
-2,052,520
-32% -$17.1M
ALNA
2
DELISTED
Allena Pharmaceuticals
ALNA
$3.63M 10.71%
2,790,964
– –
RVMD icon
3
Revolution Medicines
RVMD
$40.2B
– –
-1,909,317
Closed -$87.6M

Similar funds

IVAV
Index Venture Associates V St. Helier, Channel Islands, Jersey $1.46M AUM 88.05% 1-Year Est. Return
VM
Value Monitoring Menlo Park, California $1.5M AUM 13.21% 1-Year Est. Return
CL
CRV LLC Palo Alto, California $1.56M AUM 87.36% 1-Year Est. Return
GAM
GVO Asset Management Zug, Switzerland $1.07M AUM 24.36% 1-Year Est. Return
MC
Manteio Capital Jersey City, New Jersey $1.05M AUM
NC
Noked Capital Tel Aviv, Israel $946K AUM 17.1% 1-Year Est. Return
HCIG
H Capital II GP Grand Cayman, Cayman Islands $1.83M AUM
NP
Nimble Partners San Francisco, California $556K AUM 61.7% 1-Year Est. Return

TRV GP II's Q2 2021 Portfolio in Review

As of Q2 2021, TRV GP II held 3 positions worth $33.9M, down 79% from $158M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

TRV GP II withdrew a net $105M in Q2 2021, closing 1 position and reducing 1 holding. Its most notable exit was Revolution Medicines, an estimated $87.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • TRV GP II's biggest Q2 2021 reduction was Jounce Therapeutics, Inc. Common Stock, cutting an estimated $17.1M.
  • TRV GP II fully exited Revolution Medicines in Q2 2021, selling an estimated $87.6M.
  • TRV GP II's ten largest holdings make up 100% of its $33.9M portfolio in Q2 2021.
  • TRV GP II opened 0 new positions and closed 1 in Q2 2021.
  • TRV GP II's portfolio value fell 79% quarter-over-quarter to $33.9M.

Based on TRV GP II's 13F filing for Q2 2021, filed 11 Aug 2021.